

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/EP05/000562

International filing date: 18 January 2005 (18.01.2005)

Document type: Certified copy of priority document

Document details: Country/Office: EP
Number: 04100209.8
Filing date: 22 January 2004 (22.01.2004)

Date of receipt at the International Bureau: 24 February 2005 (24.02.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

10.01.05

**Europäisches
Patentamt****European
Patent Office****Office européen
des brevets****Bescheinigung****Certificate****Attestation**

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

04100209.8

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

PCT/EP200 5/ 0 0 0 5 6 2

18.01.05

Anmeldung Nr.:
Application no.: 04100209.8
Demande no:

Anmeldetag:
Date of filing: 22.01.04
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Akzo Nobel N.V.
Velperweg 76
6824 BM Arnhem
PAYS-BAS

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se référer à la description.)

LAWSONIA INTRACELLULARIS 43 kD SUBUNIT VACCINE

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s)
revendiquée(s)

Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

C07K14/00

Am Anmeldetag benannte Vertragsstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL
PT RO SE SI SK TR LI

Lawsonia intracellularis 43 kD subunit vaccine.

The present invention relates i.a. to nucleic acids encoding novel *Lawsonia intracellularis* proteins, to DNA fragments, recombinant DNA molecules and live recombinant carriers comprising these sequences, to host cells comprising such nucleic acids, DNA fragments, recombinant DNA molecules and live recombinant carriers, to proteins encoded by these nucleotide sequences and to their use for the manufacturing of vaccines, to vaccines for combating *Lawsonia intracellularis* infections and methods for the preparation thereof and to diagnostic tests for the detection of *Lawsonia intracellularis* antigens and for the detection of antibodies against *Lawsonia intracellularis*.

Porcine proliferative enteropathy (PPE or PE) has become an important disease of the modern pig industry world-wide. The disease affects 15% to 50% of the growing herds and up to 30% of the individual animals in established problem herds. Today annual economical losses have been estimated US\$ 5-10 in extra feed and facility time costs per affected pig. PPE is a group of chronic and acute conditions of widely differing clinical signs (death, pale and anaemic animals, watery, dark or bright red diarrhoea, depression, reduced appetite and reluctance to move, retarded growth and increased FCR). However there are two consistent features. The first, a pathological change only visible at necropsy, is a thickening of the small intestine and colon mucosa. The second is the occurrence of intracytoplasmatic small-curved bacteria in the enterocytes of the affected intestine. These bacteria have now been established as the etiological agent of PPE and have been name *Lawsonia intracellularis*.

Over the years *Lawsonia intracellularis* has been found to affect a large group of animals including monkeys, rabbits, ferrets, hamsters, fox, horses, and other animals as diverse as ostrich and emoe. *Lawsonia intracellularis* is a gram-negative, flagellated bacterium that multiplies in eukaryotic enterocytes only and no cell-free culture has been described. In order to persist and multiply in the cell *Lawsonia intracellularis* must penetrate dividing crypt cells. The bacterium associates with the cell membrane and quickly enters the

enterocyte via an entry vacuole. This then rapidly breaks down (within 3 hours) and the bacteria flourish and multiply freely in the cytoplasm. The mechanisms by which the bacteria cause infected cells to fail to mature, continue to undergo mitosis and form hypoplastic crypt cells is not yet understood.

5

The current understanding of *Lawsonia intracellularis* infection, treatment and control of the disease has been hampered by the fact that *Lawsonia intracellularis* can not be cultivated in cell-free media. Although there are reports of successful co-culturing *Lawsonia intracellularis* in rat enterocytes this has not lead to the development of inactivated vaccines for combating *Lawsonia intracellularis*, although there clearly is a need for such vaccines.

10

It is an objective of the present invention to provide a vaccine for combating *Lawsonia intracellularis* infection.

15

It was surprisingly found now, that *Lawsonia intracellularis* produces a novel protein that is capable of inducing protective immunity against *Lawsonia intracellularis*.

The novel protein will be referred to as the 43 kD protein.

20

The amino acid sequence of the novel protein is presented in sequence identifier SEQ ID NO: 2. The gene encoding this protein has been sequenced and its nucleic acid sequence is shown in sequence identifier SEQ ID NO: 1. The gene will also be referred to in the Examples as "gene 5473".

25

It is well-known in the art, that many different nucleic acid sequences can encode one and the same protein. This phenomenon is commonly known as wobble in the second and especially the third base of each triplet encoding an amino acid. This phenomenon can result in a heterology of about 30% for two nucleic acid sequences still encoding the same protein. Therefore, two nucleic acid sequences having a sequence homology of

30

about 70 % can still encode one and the same protein.

Thus, one embodiment relates to nucleic acids encoding a *Lawsonia intracellularis* protein and to parts of that nucleic acid that encode an immunogenic fragment of that protein, wherein those nucleic acids or parts thereof have a level of homology with the nucleic acid of which the sequence is given in SEQ ID NO: 1 of at least 90 %.

5

Preferably, the nucleic acid encoding this *Lawsonia intracellularis* protein or the part of said nucleic acid has at least 92 %, preferably 94 %, more preferably 95 % and even more preferably 96% homology with the nucleic acid having the sequence given in SEQ ID NO: 1. Even more preferred is a homology level of 98 % or even 100 %.

10

The level of nucleotide homology can be determined with the computer program "BLAST 2 SEQUENCES" by selecting sub-program: "BLASTN" that can be found at www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.html.

A reference for this program is Tatiana A. Tatusova, Thomas L. Madden FEMS Microbiol. Letters 174: 247-250 (1999). Parameters used are the default parameters: Reward for a match: +1. Penalty for a mismatch: -2. Open gap: 5. Extension gap: 2. Gap x_dropoff: 50.

Another approach for deciding if a certain nucleic acid is or is not a nucleic acid according to the invention relates to the question if that certain nucleic acid does hybridise under stringent conditions to nucleic acids having the nucleotide sequence as depicted in SEQ ID NO: 1.

If a nucleic acid hybridises under stringent conditions to the nucleotide sequence as depicted in SEQ ID NO: 1, it is considered to be a nucleic acid according to the invention.

25

The definition of stringent conditions follows from the formula of Meinkoth and Wahl (1984. Hybridization of nucleic acids immobilized on solid supports. Anal. Biochem. 138: 267-284.)

$$T_m = [81.5^{\circ}\text{C} + 16.6(\log M) + 0.41(\%GC) - 0.61(\%\text{formamide}) - 500/L] - 1^{\circ}\text{C}/1\%\text{mismatch}$$

30

In this formula, M is molarity of monovalent cations; %GC is the percentage of guanosine and cytosine nucleotides in the DNA; L is the length of the hybrid in base pairs.

5

Stringent conditions are those conditions under which nucleic acids or fragments thereof still hybridise, if they have a mismatch of 10% at the most, to the nucleic acid having the sequence depicted in SEQ ID NO: 1.

10

Since the present invention discloses nucleic acids encoding novel *Lawsonia intracellularis* proteins, it is now for the first time possible to obtain these proteins in sufficient quantities. This can e.g. be done by using expression systems to express the genes encoding the proteins.

15

Therefore, in a more preferred embodiment, the invention relates to DNA fragments comprising a nucleic acid according to the invention. Such DNA fragments can e.g. be plasmids, into which a nucleic acid according to the invention is cloned. Such DNA fragments are e.g. useful for enhancing the amount of DNA for use as a primer, as described below.

20

An essential requirement for the expression of the nucleic acid is an adequate promoter functionally linked to the nucleic acid, so that the nucleic acid is under the control of the promoter. It is obvious to those skilled in the art that the choice of a promoter extends to any eukaryotic, prokaryotic or viral promoter capable of directing gene transcription in cells used as host cells for protein expression.

25

Therefore, an even more preferred form of this embodiment relates to a recombinant DNA molecule comprising a DNA fragment or a nucleic acid according to the invention that is placed under the control of a functionally linked promoter. This can be accomplished by means of e.g. standard molecular biology techniques. (Sambrook, J. and Russell, D.W., Molecular cloning: a laboratory manual, 2001. ISBN 0-87969-577-3).

30

Functionally linked promoters are promoters that are capable of controlling the transcription of the nucleic acids to which they are linked.

Such a promoter can be a *Lawsonia* promoter e.g. the promoter involved in *in vivo* expression of the gene encoding the 43 kD protein, provided that that promoter is functional in the cell used for expression. It can also be a heterologous promoter. When the host cells are bacteria, useful expression control sequences which may be used

5 include the Trp promoter and operator (Goeddel, et al., Nucl. Acids Res., 8, 4057, 1980); the lac promoter and operator (Chang, et al., Nature, 275, 615, 1978); the outer membrane protein promoter (Nakamura, K. and Inouge, M., EMBO J., 1, 771-775, 1982); the bacteriophage lambda promoters and operators (Remaut, E. et al., Nucl. Acids Res., 11, 4677-4688, 1983); the α -amylase (*B. subtilis*) promoter and operator,

10 termination sequences and other expression enhancement and control sequences compatible with the selected host cell.

When the host cell is yeast, useful expression control sequences include, e.g., α -mating factor. For insect cells the polyhedrin or p10 promoters of baculoviruses can be used (Smith, G.E. et al., Mol. Cell. Biol. 3, 2156-65, 1983). When the host cell is of

15 mammalian origin illustrative useful expression control sequences include the SV-40 promoter (Berman, P.W. et al., Science, 222, 524-527, 1983) or the metallothionein promoter (Brinster, R.L., Nature, 296, 39-42, 1982) or a heat shock promoter (Voellmy et al., Proc. Natl. Acad. Sci. USA, 82, 4949-53, 1985).

20 Bacterial, yeast, fungal, insect and mammalian cell expression systems are very frequently used systems. Such systems are well-known in the art and generally available, e.g. commercially through Invitrogen (www.invitrogen.com), Novagen (www.merckbiosciences.de) or Clontech Laboratories, Inc. 4030 Fabian Way, Palo Alto, California 94303-4607, USA. Next to these expression systems, parasite-based

25 expression systems are very attractive expression systems. Such systems are e.g. described in the French Patent Application with Publication number 2 714 074, and in US NTIS Publication No US 08/043109 (Hoffman, S. and Rogers, W.: Public. Date 1 December 1993).

30 A still even more preferred form of this embodiment of the invention relates to Live Recombinant Carriers (LRCs) comprising a nucleic acid encoding the 43 kD protein or

an immunogenic fragment thereof according to the invention, a DNA fragment according to the invention or a recombinant DNA molecule according to the invention. Such carriers are e.g. bacteria and viruses. These LRCs are micro-organisms or viruses in which additional genetic information, in this case a nucleic acid encoding the 43 kD protein or an immunogenic fragment thereof according to the invention has been cloned.

Animals infected with such LRCs will produce an immunogenic response not only against the immunogens of the carrier, but also against the immunogenic parts of the protein(s) for which the genetic code is additionally cloned into the LRC, e.g. the 43 kD protein.

As an example of bacterial LRCs, attenuated Salmonella strains known in the art can attractively be used.

Live recombinant carrier parasites have i.a. been described by Vermeulen, A. N. (Int. Journ. Parasitol. 28: 1121-1130 (1998))

Also, LRC viruses may be used as a way of transporting the nucleic acid into a target cell. Live recombinant carrier viruses are also called vector viruses. Viruses often used as vectors are Vaccinia viruses (Panicali et al; Proc. Natl. Acad. Sci. USA, 79: 4927 (1982), Herpesviruses (E.P.A. 0473210A2), and Retroviruses (Valerio, D. et al; in Baum, S.J., Dicke, K.A., Lotzova, E. and Pluznik, D.H. (Eds.), Experimental Haematology today - 1988. Springer Verlag, New York: pp. 92-99 (1989)).

The technique of *in vivo* homologous recombination, well-known in the art, can be used to introduce a recombinant nucleic acid into the genome of a bacterium, parasite or virus of choice, capable of inducing expression of the inserted nucleic acid according to the invention in the host animal.

Finally another form of this embodiment of the invention relates to a host cell comprising a nucleic acid encoding a protein according to the invention, a DNA fragment comprising such a nucleic acid or a recombinant DNA molecule comprising such a nucleic acid under the control of a functionally linked promoter. This form also relates to a host cell containing a live recombinant carrier containing a nucleic acid molecule encoding a 43 kD protein or a fragment thereof according to the invention.

A host cell may be a cell of bacterial origin, e.g. *Escherichia coli*, *Bacillus subtilis* and *Lactobacillus* species, in combination with bacteria-based plasmids as pBR322, or bacterial expression vectors as pGEX, or with bacteriophages. The host cell may also be of eukaryotic origin, e.g. yeast-cells in combination with yeast-specific vector molecules, or higher eukaryotic cells like insect cells (Luckow et al; Bio-technology 6: 47-55 (1988)) in combination with vectors or recombinant baculoviruses, plant cells in combination with e.g. Ti-plasmid based vectors or plant viral vectors (Barton, K.A. et al; Cell 32: 1033 (1983), mammalian cells like Hela cells, Chinese Hamster Ovary cells (CHO) or Crandell Feline Kidney-cells, also with appropriate vectors or recombinant viruses.

Another embodiment of the invention relates to the novel proteins and to immunogenic fragments thereof according to the invention.

The concept of immunogenic fragments will be defined below.

One form of this embodiment relates i.a. to *Lawsonia intracellularis* proteins that have an amino acid sequence that is at least 90 % homologous to the amino acid sequence as depicted in SEQ ID NO: 2 and to immunogenic fragments of said protein.

In a preferred form, the embodiment relates to such *Lawsonia intracellularis* proteins that have a sequence homology of at least 92 %, preferably 94 %, more preferably 96 % homology to the amino acid sequence as depicted in SEQ ID NO: 2 and to immunogenic fragments of such proteins.

Even more preferred is a homology level of 98 % or even 100 %.

The level of protein homology can be determined with the computer program "BLAST 2 SEQUENCES" by selecting sub-program: "BLASTP", that can be found at www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.html.

A reference for this program is Tatiana A. Tatusova, Thomas L. Madden FEMS Microbiol. Letters 174: 247-250 (1999). Matrix used: "blosum62". Parameters used are the default parameters:

Open gap: 11. Extension gap: 1. Gap x_dropoff: 50.

5

It will be understood that, for the particular proteins embraced herein, natural variations can exist between individual *Lawsonia intracellularis* strains. These variations may be demonstrated by (an) amino acid difference(s) in the overall sequence or by deletions, substitutions, insertions, inversions or additions of (an) amino acid(s) in said sequence.

10

Amino acid substitutions which do not essentially alter biological and immunological activities, have been described, e.g. by Neurath et al in "The Proteins" Academic Press New York (1979). Amino acid replacements between related amino acids or

15

replacements which have occurred frequently in evolution are, inter alia, Ser/Ala, Ser/Gly, Asp/Gly, Asp/Asn, Ile/Val (see Dayhof, M.D., Atlas of protein sequence and structure, Nat. Biomed. Res. Found., Washington D.C., 1978, vol. 5, suppl. 3). Other amino acid substitutions include Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val,

20

Thr/Phe, Ala/Pro, Lys/Arg, Leu/Ile, Leu/Val and Ala/Glu. Based on this information, Lipman and Pearson developed a method for rapid and sensitive protein comparison (Science, 227, 1435-1441, 1985) and determining the functional similarity between homologous proteins. Such amino acid substitutions of the exemplary embodiments of this invention, as well as variations having deletions and/or insertions are within the scope of the invention as long as the resulting proteins retain their immune reactivity. This explains why *Lawsonia intracellularis* proteins according to the invention, when isolated from different field isolates, may have homology levels of about 90 %, while still

25

representing the same protein with the same immunological characteristics. Those variations in the amino acid sequence of a certain protein according to the invention that still provide a protein capable of inducing an immune response against infection with *Lawsonia intracellularis* or at least against the clinical manifestations of the infection are considered as "not essentially influencing the immunogenicity".

30

When a protein is used for e.g. vaccination purposes or for raising antibodies, it is however not necessary to use the whole protein. It is also possible to use a fragment of that protein that is capable, as such or coupled to a carrier such as e.g. KLH, of inducing an immune response against that protein, a so-called immunogenic fragment. An

5 "immunogenic fragment" is understood to be a fragment of the full-length protein that still has retained its capability to induce an immune response in the host, i.e. comprises a B- or T-cell epitope. At this moment, a variety of techniques is available to easily identify DNA fragments encoding antigenic fragments (determinants). The method described by Geysen et al (Patent Application WO 84/03564, Patent Application WO 86/06487, US

10 Patent NR. 4,833,092, Proc. Natl Acad. Sci. 81: 3998-4002 (1984), J. Imm. Meth. 102, 259-274 (1987), the so-called PEPSCAN method is an easy to perform, quick and well-established method for the detection of epitopes; the immunologically important regions of the protein. The method is used world-wide and as such well-known to man skilled in the art. This (empirical) method is especially suitable for the detection of B-cell epitopes.

15 Also, given the sequence of the gene encoding any protein, computer algorithms are able to designate specific protein fragments as the immunologically important epitopes on the basis of their sequential and/or structural agreement with epitopes that are now known. The determination of these regions is based on a combination of the hydrophilicity criteria according to Hopp and Woods (Proc. Natl. Acad. Sci. 78: 38248-3828 (1981)),

20 and the secondary structure aspects according to Chou and Fasman (Advances in Enzymology 47: 45-148 (1987) and US Patent 4,554,101). T-cell epitopes can likewise be predicted from the sequence by computer with the aid of Berzofsky's amphiphilicity criterion (Science 235, 1059-1062 (1987) and US Patent application NTIS US 07/005,885). A condensed overview is found in: Shan Lu on common principles: Tibtech

25 9: 238-242 (1991), Good et al on Malaria epitopes; Science 235: 1059-1062 (1987), Lu for a review; Vaccine 10: 3-7 (1992), Berzowsky for HIV-epitopes; The FASEB Journal 5:2412-2418 (1991).

Therefore, one form of still another embodiment of the invention relates to vaccines

30 capable of protecting pigs against *Lawsonia intracellularis* infection, that comprise a

protein or an immunogenic fragment thereof, according to the invention as described above together with a pharmaceutically acceptable carrier.

- 5 Still another embodiment of the present invention relates to the proteins according to the invention for use in a vaccine.

Still another embodiment relates to the use of a protein according to the invention for the manufacturing of a vaccine for combating *Lawsonia intracellularis* infections.

- 10 One way of making a vaccine according to the invention is by biochemical purification of the proteins or immunogenic fragments thereof according to the invention from bacteria obtained through mucosal scrapings taken from the infected intestine wall. This is however a very time-consuming way of making the vaccine.

- 15 It is therefore much more convenient to use the expression products of the genes encoding the proteins or immunogenic fragments thereof according to the invention in vaccines. The nucleic acid of the gene encoding the 43 kD protein is provided by the present invention.

- 20 Such vaccines based upon the expression products of these genes can easily be made by admixing a protein according to the invention or an immunogenic fragment thereof according to the invention with a pharmaceutically acceptable carrier as described below.

- Alternatively, a vaccine according to the invention can comprise live recombinant
25 carriers as described above, capable of expressing the proteins according to the invention or immunogenic fragments thereof according to the invention. Such vaccines, e.g. based upon a *Salmonella* carrier or a viral carrier infecting the enteric epithelium, or e.g. the respiratory epithelium have the advantage over subunit vaccines that they better mimic the natural way of infection of *Lawsonia intracellularis*. Moreover, their self-propagation
30 is an advantage since only low amounts of the recombinant carrier are necessary for immunisation.

Vaccines described above all contribute to active vaccination, i.e. the host's immune system is triggered by a protein according to the invention or an immunogenic fragment thereof, to make antibodies against these proteins.

- 5 Alternatively, such antibodies can be raised in e.g. rabbits or can be obtained from antibody-producing cell lines as described below. Such antibodies can then be administered to the host animal. This method of vaccination, passive vaccination, is the vaccination of choice when an animal is already infected, and there is no time to allow the natural immune response to be triggered. It is also the preferred method for
- 10 vaccinating immune-compromised animals. Administered antibodies against *Lawsonia intracellularis* can in these cases bind directly to the bacteria. This has the advantage that it immediately decreases or stops *Lawsonia intracellularis* growth.
- Therefore, one other form of this embodiment of the invention relates to vaccines comprising antibodies against the 43 kD *Lawsonia intracellularis* protein according to
- 15 the invention.

Vaccines can also be based upon host cells as described above, that comprise the proteins or immunogenic fragments thereof according to the invention.

- 20 An alternative and efficient way of vaccination is direct vaccination with DNA encoding the relevant antigen. Direct vaccination with DNA encoding proteins has been successful for many different proteins. (As reviewed in e.g. Donnelly et al., The Immunologist 2: 20-26 (1993)).

- This way of vaccination is very attractive for the vaccination of pigs against *Lawsonia intracellularis* infection.
- 25

Therefore, still other forms of this embodiment of the invention relate to vaccines comprising nucleic acids encoding a protein according to the invention or immunogenic fragments thereof according to the invention, and to vaccines comprising DNA fragments that comprise such nucleic acids.

- 30 Still other forms of this embodiment relate to vaccines comprising recombinant DNA molecules according to the invention.

DNA vaccines can easily be administered through intradermal application e.g. using a needle-less injector. This way of administration delivers the DNA directly into the cells of the animal to be vaccinated. Amounts of DNA in the microgram range between 1 and 100 μ g provide very good results.

5

In a further embodiment, the vaccine according to the present invention additionally comprises one or more antigens derived from other pig pathogenic organisms and viruses, or genetic information encoding such antigens.

Such organisms and viruses are preferably selected from the group of Pseudorabies virus,

10

Porcine influenza virus, Porcine parvo virus, Transmissible gastro-enteritis virus, Rotavirus, *Escherichia coli*, *Erysipelothrix rhusiopathiae*, *Bordetella bronchiseptica*, *Salmonella choleraesuis*, *Haemophilus parasuis*, *Pasteurella multocida*, *Streptococcus suis*, *Mycoplasma hyopneumoniae*, *Brachyspira hyodysenteriae* and *Actinobacillus pleuropneumoniae*.

15

All vaccines according to the present invention comprise a pharmaceutically acceptable carrier. A pharmaceutically acceptable carrier can be e.g. sterile water or a sterile physiological salt solution. In a more complex form the carrier can e.g. be a buffer.

20

Methods for the preparation of a vaccine comprise the admixing of a protein according to the invention, or an immunogenic fragment thereof, and a pharmaceutically acceptable carrier.

25

Vaccines according to the present invention may in a preferred presentation also contain an adjuvant. Adjuvants in general comprise substances that boost the immune response of the host in a non-specific manner. A number of different adjuvants are known in the art. Examples of adjuvants are Freund's Complete and Incomplete adjuvant, vitamin E, non-ionic block polymers, muramyl dipeptides, Quil A(R), mineral oil e.g. Bayol(R) or Markol(R), vegetable oil, and Carbopol(R) (a homopolymer), or Diluvac(R) Forte.

30

The vaccine may also comprise a so-called "vehicle". A vehicle is a compound to which the polypeptide adheres, without being covalently bound to it. Often used vehicle

compounds are e.g. aluminium hydroxide, -phosphate or -oxide, silica, Kaolin, and Bentonite.

A special form of such a vehicle, in which the antigen is partially embedded in the vehicle, is the so-called ISCOM (EP 109.942, EP 180.564, EP 242.380)

- 5 In addition, the vaccine may comprise one or more suitable surface-active compounds or emulsifiers, e.g. Span or Tween.

Often, the vaccine is mixed with stabilisers, e.g. to protect degradation-prone polypeptides from being degraded, to enhance the shelf-life of the vaccine, or to improve freeze-drying efficiency. Useful stabilisers are i.a. SPGA (Bovarnik et al; J. Bacteriology
10 59: 509 (1950)), carbohydrates e.g. sorbitol, mannitol, trehalose, starch, sucrose, dextran or glucose, proteins such as albumin or casein or degradation products thereof, and buffers, such as alkali metal phosphates.

- In addition, the vaccine may be suspended in a physiologically acceptable diluent. It goes without saying, that other ways of adjuvating, adding vehicle compounds or
15 diluents, emulsifying or stabilising a polypeptide are also embodied in the present invention.

- Vaccines according to the invention can very suitably be administered in amounts ranging between 1 and 100 micrograms, although smaller doses can in principle be used.
20 A dose exceeding 100 micrograms will, although immunologically very suitable, be less attractive for commercial reasons.

- Vaccines based upon live attenuated recombinant carriers, such as the LRC-viruses and bacteria described above can be administered in much lower doses, because they multiply
25 themselves during the infection. Therefore, very suitable amounts would range between 10^3 and 10^9 CFU/PFU for respectively bacteria and viruses.

- Many ways of administration can be applied. Oral application is a very attractive way of administration, because the infection is an infection of the digestive tract. A preferred
30 way of oral administration is the packaging of the vaccine in capsules, known and frequently used in the art, that only disintegrate after they have passed the highly acidic

environment of the stomach. Also, the vaccine could be mixed with compounds known in the art for temporarily enhancing the pH of the stomach.

Systemic application is also suitable, e.g. by intramuscular application of the vaccine. If this route is followed, standard procedures known in the art for systemic application are well-suited.

From a point of view of protection against disease, a quick and correct diagnosis of *Lawsonia intracellularis* infection is important.

Therefore it is another objective of this invention to provide diagnostic tools suitable for the detection of *Lawsonia intracellularis* infection.

A diagnostic test for the detection of *Lawsonia intracellularis* antibodies in sera can be e.g. a simple standard sandwich-ELISA-test in which 43 kD protein or antigenic fragments thereof according to the invention are coated to the wall of the wells of an ELISA-plate. A method for the detection of such antibodies is e.g. incubation of 43 kD protein or antigenic fragments thereof with serum from mammals to be tested, followed by e.g. incubation with a labelled antibody against the relevant mammalian antibody. A colour reaction can then reveal the presence or absence of antibodies against *Lawsonia intracellularis*. Another example of a diagnostic test system is e.g. the incubation of a Western blot comprising the 43 kD protein or an antigenic fragment thereof according to the invention, with serum of mammals to be tested, followed by analysis of the blot.

Thus, another embodiment of the present invention relates to diagnostic tests for the detection of antibodies against *Lawsonia intracellularis*. Such tests comprise a protein or a fragment thereof according to the invention.

A diagnostic test based upon the detection of antigenic material of the specific 43 kD protein of *Lawsonia intracellularis* antigens and therefore suitable for the detection of *Lawsonia intracellularis* infection can e.g. also be a standard ELISA test. In one example of such a test the walls of the wells of an ELISA plate are coated with antibodies directed against the 43 kD protein. After incubation with the material to be tested, labelled anti-

Lawsonia intracellularis antibodies are added to the wells. A colour reaction then reveals the presence of antigenic material from *Lawsonia intracellularis*.

Therefore, still another embodiment of the present invention relates to diagnostic tests for the detection of antigenic material of *Lawsonia intracellularis*. Such tests comprise
 5 antibodies against a protein or a fragment thereof according to the invention.

The polypeptides or immunogenic fragments thereof according to the invention expressed as characterised above can be used to produce antibodies, which may be polyclonal, monospecific or monoclonal (or derivatives thereof). If polyclonal antibodies are desired,
 10 techniques for producing and processing polyclonal sera are well-known in the art (e.g. Mayer and Walter, eds. *Immunochemical Methods in Cell and Molecular Biology*, Academic Press, London, 1987).

Monoclonal antibodies, reactive against the polypeptide according to the invention (or variants or fragments thereof) according to the present invention, can be prepared by
 15 immunising inbred mice by techniques also known in the art (Kohler and Milstein, *Nature*, 256, 495-497, 1975).

Methods for large-scale production of antibodies according to the invention are also known in the art. Such methods rely on the cloning of (fragments of) the genetic
 20 information encoding the protein according to the invention in a filamentous phage for phage display. Such techniques are described i.a. at the "Antibody Engineering Page" under "filamentous phage display" at <http://aximt1.imt.uni-marburg.de/~rek/aepphage.html>, and in review papers by Cortese, R. et al., (1994) in Trends Biotechn. 12: 262-267., by Clackson, T. & Wells, J.A. (1994) in Trends Biotechn. 12: 173-183, by Marks, J.D. et al., (1992) in J. Biol. Chem. 267: 16007-16010, by Winter, G. et al., (1994) in Annu. Rev. Immunol. 12: 433-455, and by Little, M. et al., (1994) Biotechn. Adv. 12: 539-555. The phages are subsequently used to screen camelid expression libraries expressing camelid heavy chain antibodies. (Muyldermans, S. and Lauwereys, M., Journ. Molec. Recogn. 12: 131-140 (1999) and Ghahroudi, M.A. et al.,
 25 FEBS Letters 414: 512-526 (1997)). Cells from the library that express the desired
 30

antibodies can be replicated and subsequently be used for large scale expression of antibodies.

Examples

Example 1:

Isolation of *Lawsonia intracellularis* from infected porcine ilea.

- 5 *L. intracellularis* infected ilea, confirmed by histopathology and acid-fast Ziehl-Neelsen or Whartin-Starry staining, were collected from pigs died with PE, and stored at -80°C. After thawing *L. intracellularis* bacteria were isolated from mucosal scrapings taken from the infected intestinal wall. The ileal scrapings were homogenized repeatedly in PBS in an omnimixer to release the intracellular bacteria as described by Lawson et al. (Vet. Microbiol. 10: 303-323 (1985)). Supernatant obtained after low-speed centrifugation to remove cell debris was filtered through 5.0, 3.0, 1.2, and 0.8 µm filters (Millipore). The filtrate was subsequently centrifuged at 8000 g for 30 min, giving a small pellet of *L. intracellularis* bacteria. These bacteria were further purified using a Percoll gradient. The identity of the purified bacteria was assessed by PCR (Jones et al., J. Clin. Microbiol. 31: 2611-2615 (1993)) whereas purity of the isolated bacteria (>95%) was assessed by phase contrast microscopy to reveal any contaminating bacteria or gut debris present.

Bacterial strains and plasmids

- L. intracellularis* cells were isolated from infected ileal material as described above.
- 20 *E. coli* strain TOP10F' and the TOPO TA cloning kit, containing plasmid pCR2.1 TOPO TA were purchased from Invitrogen (Groningen, the Netherlands). Stocks of all bacterial strains, containing 30% glycerol, were stored at -70°C.
- Luria Bertani broth (LB) and LB plates were prepared according to standard procedures. When needed plasmids were transformed to *E. coli* TOP10F' competent cells by heat shock. *E. coli* cells were made competent using standard methods.

DNA isolation

- In order to obtain highly purified *L. intracellularis* chromosomal DNA, DNA was prepared from bacterial cells using a Biorad chromosomal DNA isolation kit (Biorad, Veenendaal, the Netherlands) according to manufacturers instructions. Plasmid DNA and

linear DNA was isolated using Qiagen products according to the protocols provided by the manufacturer.

PCR amplification

- 5 PCR amplification was performed using a Geneamp 9700 PCR system (Applied Biosystems, California, USA). The PCR was performed with the Expand High Fidelity PCR System (Roche Diagnostics GmbH, Mannheim, Germany). The PCR mixture contained 52 U/ml Expand High Fidelity Enzyme Mix, Expand HF buffer with 2.5 mM $MgCl_2$, 16 mM dNTPs (Promega, Wisconsin, USA), 20 pmoles of primers and 15 ng
- 10 chromosomal DNA of *L. intracellularis* as template.
- For standard applications (i.e. colony PCR) the PCR mixture contained 20 U/ml Supertaq and Supertaq buffer (HT Biotechnology Ltd, Cambridge, UK), containing 8 mM dNTPs (Promega, Wisconsin, USA), 10 pmoles of primers and 15 ng template.

15 In vitro transcription and translation

- In vitro transcription and translation was performed using the Rapid Translation System from Roche Applied Science (Mannheim, FRG) according the manufacturer's protocol. Summarizing, first the knowledge based sequence-optimization tool ProteoExpert RTS E. coli HY was used to design high yield variants of the original gene. This program
- 20 optimizes the DNA template for the translation step by suggesting mutations in the DNA sequence. Only silent mutations were allowed, leading to identical amino-acid sequences on the protein level. However, changes of up to 8 nucleotides within the first 6 codons were proposed by the ProteoExpert service to give better expression results.
- Ten sense and a universal antisense primers, containing a 5' overlapping region of 20
- 25 nucleotides and 30-38 additional gene-specific nucleotides, were used in 10 different PCR reactions to amplify these variants with purified *L. intracellularis* chromosomal DNA as template. The obtained amplicons were purified from gel and used for the generation of linear expression constructs for cell-free protein expression using the RTS E. coli Linear Template Generation Set, His-tag, to introduce the necessary T7 regulatory
- 30 elements.

Again the obtained amplicons were purified from gel, and after quantification, the appropriate amount of DNA was used for protein expression analysis in a 50- μ l RTS 100 E. coli HY reaction mixture. Expression was analysed using Western blotting with an anti polyhistidine monoclonal antibody.

- 5 The construct that gave the highest protein yields was ligated to pCR2.1 TOPO TA vector using the TOPO TA cloning kit. The obtained plasmid was used for medium scale protein production using the RTS 500 E. coli HY kit. The samples were analyzed by SDS page and by Western blot.

- 10 The DNA sequence of the expression vector was confirmed using an ABI 310 automated sequencer (Applied Biosystems, California, USA).

If needed protein was purified using TALON immobilized metal affinity chromatography resin according to the protocol of the manufacturer for purification using denaturing conditions. Subsequently, the purified protein fraction was dialyzed against PBS to remove urea from the sample.

15

Polyacrylamide gel electrophoresis and western blotting

SDS-PAGE was performed using 4-12% Bis-Tris gels from the NuPAGE electrophoresis system (Novex, San Diego, USA). Western blotting was performed using semi dry blotting procedures. Western blots were developed using chicken anti-Lawsonia polyclonal serum and pig anti-Lawsonia polyclonal serum that were raised against a whole cell preparation in a water:oil=45:55 emulsion. The sera were pre-adsorbed using an equal volume crude cell extracts from BL21 star(DE3) containing vector pLysSrare at 4°C for 4 hours.

20

Results

25

Cloning of *L. intracellularis* gene 5473

For the evaluation of the ProteoExpert suggestions, linear DNA templates were generated via PCR using the RTS Linear Template Generation Set. The primers used in these experiments also introduced a His6-tag at the C-terminus for detection and purification. The PCR-generated templates were examined for their expression performance using

30

RTS 100 E. coli HY Kit. The suggested DNA sequence that gave the highest yields was constructed using primers 5473A2 and 5473B (Table 1) in the first PCR.

The obtained expression construct was ligated to pCR2.1 TOPO TA vector and the resulting vector was transformed to *E. coli* TOP10F and incubated o/n at 37°C. Putative transformants were checked for the right plasmid, using colony PCR. The plasmid inserts, of colony PCR positive transformants, were checked by nucleotide sequence analysis. One of the clones that contained a sequence as expected on basis of the cloning strategy was chosen and designated pTOPO5473.

10 Table 1. Sequence of the degenerated primers used for the amplification of gene 5473.

Primer	Sequence
5473A2	CTTTAAGAAGGAGATATACCATG ACAAATTTTGGAGATATTAGCGGAAGCTCCG
5473B	TGATGATGAGAACCCCCCCCCTCACGTGCACCA

Expression of *L. intracellularis* gene 5473 using RTS technology

Plasmid pTOPO5473 was purified from *E. coli* TOP10F and the appropriate amount of

15 DNA was added to a RTS500 vial. After incubation conform the protocol of the manufacturer, a sample was taken for analysis using SDS-PAGE gel electrophoresis (Fig. 1A). However, it was impossible to see whether the reaction mixture had produced a protein of around 40 kDa because the mixture already contains a dominant protein of around 40 kDa (Fig. 1A, lane 2 and 4). The RTS 500 reaction containing pTOPO5473 and the control mixture were loaded onto a IMAC column and proteins that had bound to

20 the column were analyzed using SDS-PAGE. From the gel it appeared that a 43 kDa protein was eluted from the column (Fig 1A, lane 5) that was not purified from the control sample (Fig. 1A, lane 3), so protein was expressed.

The same samples were also analysed by Western blot using pig-derived and chicken-derived *L. intracellularis* anti-serum. A reaction with the 43 kD protein was observed

25 both using serum from *L. intracellularis* bacterin vaccinated pigs (Fig 1B, lane 5) and chickens (Fig 1C, lane 5).

Conclusion: The 43 kD protein according to the invention can be efficiently expressed. Moreover, antiserum raised against *Lawsonia intracellularis* cells from both chickens and pigs recognises the expressed protein. The 43 kD protein is an important vaccine
5 component for the protection of pigs against *Lawsonia intracellularis* infection.

Legend to the figure.

Fig. 1. Analysis of the expression of *Lawsonia intracellularis* gene 5473 using RTS500 technology by SDS-PAGE (A) and Western blotting with polyclonal pig serum (B) and polyclonal chicken serum(C). Lane 1, molecular weight marker; lane 2, control; lane 3, bound protein fraction IMAC purification controle sample; lane 4 pET5473; lane 5, bound protein fraction IMAC purification pET5473. Arrows indicate the location of the expression product.

Claims

- 1) Nucleic acid encoding a 43 kD *Lawsonia intracellularis* protein or a part of said nucleic acid that encodes an immunogenic fragment of said protein, said nucleic acid or said part thereof having at least 90 %, preferably 92 %, more preferably 94 %, even more preferably 96% homology with a nucleic acid having a sequence as depicted in SEQ ID NO: 1
- 2) DNA fragment comprising a nucleic acid according to claim 1.
- 3) Recombinant DNA molecule comprising a nucleic acid according to claim 1 or a DNA fragment according to claim 2, under the control of a functionally linked promoter.
- 4) Live recombinant carrier comprising a nucleic acid according to claim 1, a DNA fragment according to claim 2 or a recombinant DNA molecule according to claim 3.
- 5) Host cell comprising a nucleic acid according to claim 1, a DNA fragment according to claim 2, a recombinant DNA molecule according to claim 3 or a live recombinant carrier according to claim 4.
- 6) A 43 kD *Lawsonia intracellularis* protein, said protein comprising an amino acid sequence that is at least 90 %, preferably 92 %, more preferably 94 %, even more preferably 96 % homologous to the amino acid sequence as depicted in SEQ ID NO: 2, or an immunogenic fragment of said protein.
- 7) *Lawsonia intracellularis* protein according to claim 6 for use in a vaccine.
- 8) Use of a *Lawsonia intracellularis* protein according to claim 6 for the manufacturing of a vaccine for combating *Lawsonia intracellularis* infections.
- 9) Vaccine for combating *Lawsonia intracellularis* infections, characterised in that it comprises a nucleic acid according to claim 1, a DNA fragment according to claim 2, a recombinant DNA molecule according to claim 3, a live recombinant carrier according to claim 4, a host cell according to claim 5 or a protein according to claim 6, and a pharmaceutically acceptable carrier.
- 10) Vaccine according to claim 9, characterised in that it comprises an adjuvant.

- 11) Vaccine according to claim 9 or 10, characterised in that it comprises an additional antigen derived from a virus or micro-organism pathogenic to pigs or genetic information encoding said antigen.
- 12) Vaccine according to claim 11, characterised in that said virus or micro-organism pathogenic to pigs is selected from the group of Pseudorabies virus, Porcine influenza virus, Porcine parvo virus, Transmissible gastro-enteritis virus, Rotavirus, *Escherichia coli*, *Erysipelothrix rhusiopathiae*, *Bordetella bronchiseptica*, *Salmonella choleraesuis*, *Haemophilus parasuis*, *Pasteurella multocida*, *Streptococcus suis*, *Mycoplasma hyopneumoniae*, *Brachyspira hyodysenteriae* and *Actinobacillus pleuropneumoniae*.
- 13) Vaccine for combating *Lawsonia intracellularis* infections, characterised in that it comprises antibodies against a protein according to claim 6.
- 14) Method for the preparation of a vaccine according to claim 9-13, said method comprising the admixing of a nucleic acid according to claim 1, a DNA fragment according to claim 2, a recombinant DNA molecule according to claim 3, a live recombinant carrier according to claim 4, a host cell according to claim 5, a protein according to claim 6, or antibodies against a protein according to claim 6, and a pharmaceutically acceptable carrier.
- 15) Diagnostic test for the detection of antibodies against *Lawsonia intracellularis*, characterised in that said test comprises a protein or a fragment thereof as defined in claim 6.
- 16) Diagnostic test for the detection of antigenic material of *Lawsonia intracellularis*, characterised in that said test comprises antibodies against a protein or a fragment thereof as defined in claim 6.

Abstract

The present invention relates i.a. to nucleic acids encoding novel *Lawsonia intracellularis* proteins. It furthermore relates to DNA fragments, recombinant DNA molecules and live
5 recombinant carriers comprising these sequences. Also it relates to host cells comprising such nucleic acids, DNA fragments, recombinant DNA molecules and live recombinant carriers. Moreover, the invention relates to proteins encoded by these nucleotide sequences and to their use for the manufacturing of vaccines. The invention also relates to vaccines for combating *Lawsonia intracellularis* infections and methods for the
10 preparation thereof. Finally the invention relates to diagnostic tests for the detection of *Lawsonia intracellularis* antigens and of antibodies against *Lawsonia intracellularis*.




Figure 1.

SEQUENCE LISTING

<110> AKZO Nobel N.V.

<120> Lawsonia intracellularis 43 kD subunit vaccine

<130> 2004.008

<160> 2

<170> PatentIn version 3.2

<210> 1

<211> 1269

<212> DNA

<213> Lawsonia intracellularis

<220>

<221> CDS

<222> (32)..(1222)

<400> 1

tggtggaaat tctctctgga ggagtaaagc a atg aca aat ttt gga gat ata	52
Met Thr Asn Phe Gly Asp Ile	
1 5	
agc gga agc tcc gca aga atg agt agc ttg atg act ggt aca tcc ggt	100
Ser Gly Ser Ser Ala Arg Met Ser Ser Leu Met Thr Gly Thr Ser Gly	
10 15 20	
gaa gaa gga ctt gaa gaa ctt gaa ggt ggt gtt cct aaa gag caa ggt	148
Glu Glu Gly Leu Glu Glu Leu Glu Gly Gly Val Pro Lys Glu Gln Gly	
25 30 35	
ggt cca ggt aaa gga gat gct tca gag gct gct aaa ggt caa gca gca	196
Gly Pro Gly Lys Gly Asp Ala Ser Glu Ala Ala Lys Gly Gln Ala Ala	
40 45 50 55	
gca gat agt att aat tca gct ggt ggt act gaa aag cct gga gaa gtt	244
Ala Asp Ser Ile Asn Ser Ala Gly Gly Thr Glu Lys Pro Gly Glu Val	
60 65 70	
ggt gat aag gaa gat gta ggg gaa ggt ggc gaa ata cct gaa ggt ggt	292
Gly Asp Lys Glu Asp Val Gly Glu Gly Gly Glu Ile Pro Glu Gly Gly	
75 80 85	
gaa ata cct gag ggt ggt gaa gaa gtt cca gag gaa ccc cca tat gtc	340
Glu Ile Pro Glu Gly Gly Glu Glu Val Pro Glu Glu Pro Pro Tyr Val	
90 95 100	
cct cct cca ttg gtt gaa cca gct aaa atc agt aca gta aca gat ctc	388
Pro Pro Pro Leu Val Glu Pro Ala Lys Ile Ser Thr Val Thr Asp Leu	
105 110 115	
agt acg tta atg gga tca cta cag ctg aca gag caa aaa aag aat gct	436
Ser Thr Leu Met Gly Ser Leu Gln Leu Thr Glu Gln Lys Lys Asn Ala	
120 125 130 135	
gaa aaa aca gta aat gaa att aaa gca cag aat aaa gag caa caa gta	484
Glu Lys Thr Val Asn Glu Ile Lys Ala Gln Asn Lys Glu Gln Gln Val	
140 145 150	
aag ttc caa gag caa att aaa aag att gag gat aat att gct gaa tct	532
Lys Phe Gln Glu Gln Ile Lys Lys Ile Glu Asp Asn Ile Ala Glu Ser	
155 160 165	

aag aaa agt ggt ata ctt aag ttt ttc caa aag ttg ttt gca gtt att 580
 Lys Lys Ser Gly Ile Leu Lys Phe Phe Gln Lys Leu Phe Ala Val Ile
 170 175 180
 ggt gct gta cta gga gct att gga ggt gcg cta gct att gct gca ggt 628
 Gly Ala Val Leu Gly Ala Ile Gly Gly Ala Leu Ala Ile Ala Ala Gly
 185 190 195
 gct gct tca ggt aac cca tta ttg gtt gct gca ggt att atg gct att 676
 Ala Ala Ser Gly Asn Pro Leu Leu Val Ala Ala Gly Ile Met Ala Ile
 200 205 210 215
 gta gct tca att gat gca gca atg tcg tcg cta tcg gat ggt aaa gtg 724
 Val Ala Ser Ile Asp Ala Ala Met Ser Ser Leu Ser Asp Gly Lys Val
 220 225 230
 tcc atc tca gca ggg att agt aag gct ctt gag gct atg gga gta cca 772
 Ser Ile Ser Ala Gly Ile Ser Lys Ala Leu Glu Ala Met Gly Val Pro
 235 240 245
 gca gaa aca gca caa tgg att gca ttt ggt ata cag tta gca atg att 820
 Ala Glu Thr Ala Gln Trp Ile Ala Phe Gly Ile Gln Leu Ala Met Ile
 250 255 260
 gca gtg act ata gct att ggt ttt gcc tct ggt ggt gga gca atg 868
 Ala Val Thr Ile Ala Ile Gly Phe Ala Ser Gly Gly Gly Gly Ala Met
 265 270 275
 gct gga gtg tca aaa ata gca gat atg ttt tca aag tct caa gat gta 916
 Ala Gly Val Ser Lys Ile Ala Asp Met Phe Ser Lys Ser Gln Asp Val
 280 285 290 295
 gct aag ttg gca cag atg att gaa aaa gct tct aaa ata gta caa atc 964
 Ala Lys Leu Ala Gln Met Ile Glu Lys Ala Ser Lys Ile Val Gln Ile
 300 305 310
 gct ggt tca gtt aat cag tct gct ata gcc ggt aca ggt att ggt aca 1012
 Ala Gly Ser Val Asn Gln Ser Ala Ile Gly Gly Thr Gly Ile Gly Thr
 315 320 325
 gct gta gtg caa agc aat ata aaa gct aat gaa tct gaa caa aaa gaa 1060
 Ala Val Val Gln Ser Asn Ile Lys Ala Asn Glu Ser Glu Gln Lys Glu
 330 335 340
 att gaa gct gct att gca aaa gtt aaa gct aag ata gag acg tta caa 1108
 Ile Glu Ala Ala Ile Ala Lys Val Lys Ala Lys Ile Glu Thr Leu Gln
 345 350 355
 gac ttc ttt aaa aac caa atg gaa caa ttc aat gct ata atg aaa ata 1156
 Asp Phe Phe Lys Asn Gln Met Glu Gln Phe Asn Ala Ile Met Lys Ile
 360 365 370 375
 ata aca gat att att caa gat agc gtc aat aca aaa ata gct gtt caa 1204
 Ile Thr Asp Ile Ile Gln Asp Ser Val Asn Thr Lys Ile Ala Val Gln
 380 385 390
 cgt ggt gca cgt gag taa taccttagt aaatacagtg actatactat 1252
 Arg Gly Ala Arg Glu
 395
 aatatataaa ttaataa 1269

<210> 2
 <211> 396
 <212> PRT
 <213> Lawsonia intracellularis

<400> 2

Met Thr Asn Phe Gly Asp Ile Ser Gly Ser Ser Ala Arg Met Ser Ser
1 5 10 15

Leu Met Thr Gly Thr Ser Gly Glu Glu Gly Leu Glu Glu Leu Glu Gly
20 25 30

Gly Val Pro Lys Glu Gln Gly Gly Pro Gly Lys Gly Asp Ala Ser Glu
35 40 45

Ala Ala Lys Gly Gln Ala Ala Ala Asp Ser Ile Asn Ser Ala Gly Gly
50 55 60

Thr Glu Lys Pro Gly Glu Val Gly Asp Lys Glu Asp Val Gly Glu Gly
65 70 75 80

Gly Glu Ile Pro Glu Gly Gly Glu Ile Pro Glu Gly Gly Glu Glu Val
85 90 95

Pro Glu Glu Pro Pro Tyr Val Pro Pro Pro Leu Val Glu Pro Ala Lys
100 105 110

Ile Ser Thr Val Thr Asp Leu Ser Thr Leu Met Gly Ser Leu Gln Leu
115 120 125

Thr Glu Gln Lys Lys Asn Ala Glu Lys Thr Val Asn Glu Ile Lys Ala
130 135 140

Gln Asn Lys Glu Gln Gln Val Lys Phe Gln Glu Gln Ile Lys Lys Ile
145 150 155 160

Glu Asp Asn Ile Ala Glu Ser Lys Lys Ser Gly Ile Leu Lys Phe Phe
165 170 175

Gln Lys Leu Phe Ala Val Ile Gly Ala Val Leu Gly Ala Ile Gly Gly
180 185 190

Ala Leu Ala Ile Ala Ala Gly Ala Ala Ser Gly Asn Pro Leu Leu Val
195 200 205

Ala Ala Gly Ile Met Ala Ile Val Ala Ser Ile Asp Ala Ala Met Ser
210 215 220

Ser Leu Ser Asp Gly Lys Val Ser Ile Ser Ala Gly Ile Ser Lys Ala
225 230 235 240

Leu Glu Ala Met Gly Val Pro Ala Glu Thr Ala Gln Trp Ile Ala Phe
245 250 255

Gly Ile Gln Leu Ala Met Ile Ala Val Thr Ile Ala Ile Gly Phe Ala
260 265 270

Ser Gly Gly Gly Gly Ala Met Ala Gly Val Ser Lys Ile Ala Asp Met
 275 280 285

Phe Ser Lys Ser Gln Asp Val Ala Lys Leu Ala Gln Met Ile Glu Lys
 290 295 300

Ala Ser Lys Ile Val Gln Ile Ala Gly Ser Val Asn Gln Ser Ala Ile
 305 310 315 320

Gly Gly Thr Gly Ile Gly Thr Ala Val Val Gln Ser Asn Ile Lys Ala
 325 330 335

Asn Glu Ser Glu Gln Lys Glu Ile Glu Ala Ala Ile Ala Lys Val Lys
 340 345 350

Ala Lys Ile Glu Thr Leu Gln Asp Phe Phe Lys Asn Gln Met Glu Gln
 355 360 365

Phe Asn Ala Ile Met Lys Ile Ile Thr Asp Ile Ile Gln Asp Ser Val
 370 375 380

Asn Thr Lys Ile Ala Val Gln Arg Gly Ala Arg Glu
 385 390 395